Are you being treated with Darolutamide for metastatic castration-sensitive prostate cancer? Then we want to hear from you!
The purpose of this survey is to provide CCSN with insights and perspectives about living with and managing prostate cancer from patients and caregivers to complete a patient evidence submission for a new medication for metastatic castration-sensitive prostate cancer called darolutamide.
If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
The pan-Canadian Oncology Drug Review invites patient groups like the Canadian Cancer Survivor Network (CCSN) to prepare and send in submissions so that patients like you can be heard. Please join us and have your voice included in this important submission process.
Thank you for your participation.